Carlos Fernández-Hernando, PhD, Appointed Director of Vascular Biology & Therapeutics Program at Yale School of Medicine
Carlos Fernández-Hernando, PhD, Anthony N. Brady Professor of Comparative Medicine and Pathology, was appointed as Director of the Vascular Biology & Therapeutics Program at Yale School of Medicine effective February 1.
Dr. Nassiri is selected to the International Society for Study of Vascular Anomalies (ISSVA) task force on classification of vascular anomalies
Dr. Nassiri is selected to represent the United States and the Specialty of Vascular Surgery on the International Society for Study of Vascular Anomalies (ISSVA) Ad-hoc Committee for Classification of Vascular Anomalies.Source: ISSVA Newsletter Vol 5 - No 1 | April 2021
The Yale Vascular Malformations Program (VaMP) identifies a culprit gene mutation implicated in the pathogenesis of "hepatic hemangiomas".
The Yale New Haven Hospital Vascular Malformations Program (VaMP), via a collaborative multidisciplinary effort, has identified somatic mosaic gene mutations (GJA4 encoding connexin 37) implicated in the pathogenesis of so-called “HEPATIC HEMANGIOMAS” in adult patients. This discovery questions the validity of the very term “hemangioma” in this particular anatomic distribution; and renders – for the first time - objective scientific support to the radiographically and clinically suspected notion that these lesions actually represent VENOUS MALFORMATIOMS - an entity with a completely different natural history, hemodynamics, angioarchitectural profile, and ergo therapeutic susceptibility.Source: Cutaneous and hepatic vascular lesions due to a recurrent somatic GJA4 mutation reveal a pathway for vascular malformation